Elsevier

Gynecologic Oncology

Volume 126, Issue 3, September 2012, Pages 403-407
Gynecologic Oncology

Unraveling the two entities of endometrioid ovarian cancer: A single center clinical experience

https://doi.org/10.1016/j.ygyno.2012.05.007Get rights and content

Abstract

Objective

Due to the increasing prevalence of the benign condition, ovarian carcinoma arising from endometriosis is emerging as a relevant clinical entity with an unclear biological signature. We have investigated clinical and histologic features of endometriosis-associated endometrioid ovarian cancer using an institutional retrospective database.

Methods

Patients diagnosed with endometrioid ovarian cancer at our institution were divided into two groups according to the fulfillment or not of Sampson's and Scott's criteria for the detection of endometriosis-associated ovarian cancer. Clinical and histological data were reported and compared. Survival analysis was obtained using the log-rank test in an unadjusted Kaplan–Meier method. Multivariate analysis was performed using the Cox proportional hazards regression model to establish independent factors associated with endometriosis-associated endometrioid ovarian cancer and to identify predictors of survival. The degree of concordance was evaluated by Cohen's Kappa measures.

Results

Patients with endometriosis-associated endometrioid ovarian cancer were significantly younger, had a lower disease stage (62% vs 23%; p = 0.003), a less prevalent high grade tumor (38% vs 82%; p = 0.002) and a higher prevalence of squamous and mucinous metaplasia. The rate of endometrial cancer diagnosis was significantly higher in women with endometriosis-associated endometrioid ovarian cancer (33%) than in other patients (11%) (p = 0.04) with a 92% concordance between ovarian and endometrial histologic tumor grade. A significant difference in survival rate could not be demonstrated between patients with or without endometriosis.

Conclusions

The analysis of a retrospective endometrioid ovarian cancer database may allow to suggest a 40 molecular, morphological and clinical parallelism between endometrial and endometrioid ovarian cancers.

Highlights

► Endometriosis-associated endometrioid ovarian tumors possess a different biologic signature when compared to cancers not associated with the disease. ► Clinical and molecular features of the two types of endometrial cancer reflect those of endometriosis-associated and non-associated endometrioid ovarian tumor.

Introduction

The potential for neoplastic degeneration of ovarian endometriotic cysts has been debated over the past decade from biological, epidemiological and clinical perspectives [1], [2], [3], [4], [5]. This issue is of particular clinical relevance given the high incidence of endometriosis, a disease affecting an estimated 14 million women of reproductive age in the European Union alone [6]. The life-threatening characteristics of ovarian cancer, a tumor with a 5-year overall survival of less than 40%, make the issue even more critical. Indeed, based on a comprehensive literature search, a significant association between endometriosis and ovarian cancer has been supported by at least six sufficiently powered epidemiological studies [1], [7], [8], [9], [10], [11]. In addition, when the presence of endometriosis has been related to the cancer histotypes, it was clear that tumors arising from endometriosis were confined to specific subcategories of disease [3]. A strong association between endometriosis and both endometrioid and clear cell ovarian cancers has long been known, although the adoption of strict criteria for the pathological analysis has prevented for decades the recognition of ectopic endometrium as the definitive site of origin of these gonadal malignancies [3], [12]. Currently, atypical endometriosis, observed in 1–3% of endometriotic cysts [13], is considered the precursor lesion for most endometrioid and clear cell ovarian cancers and the risk of detecting these histotypes is estimated to be about 4-fold higher in women with endometriosis [14].

A keenly debated topic in literature is whether endometriosis-associated cancer represents a clinicopathologic entity distinct from other forms of ovarian cancers [13], [14], [15]. Indeed, increased awareness of the characteristics of these tumors would improve early detection of patients at risk. To this aim, some studies have investigated the clinical behavior and prognostic factors in ovarian cancer patients with or without concomitant endometriosis. In general, they suggest, albeit not consistently, that patients with endometriosis tend to be younger and to be diagnosed in earlier stages and with lower grade lesions [16], [17], [18]. Other studies have tried to establish the histological features characterizing these ovarian cancers. Reports are however heterogeneous with controversial results in terms of prevalence and significance of metaplastic, hyperplastic or atypical changes associated with the malignant lesions [3]. Importantly, very few of these studies have specifically evaluated differences in prognostic factors and histological findings between cancers of similar histotypes [11], [19], [20], [21], [22], [23], [24]. The comparisons have been mostly performed with cases of ovarian epithelial cancer in general, thus probably introducing some sources of bias.

In this study, we have evaluated the clinical and histological features of endometriosis-associated ovarian cancers of the endometrioid histotype specifically and compared them with those of endometrioid tumors without endometriosis. Based on the combination of the results obtained herein and of findings derived from the molecular pattern, some potentially interesting observations on the pathogenesis of endometrioid ovarian cancer have been suggested as a potential novel theory.

Section snippets

Methods

After obtaining ethical approval from San Raffaele Institute Ethics Board, the study population was identified through a search on the Gynecological Malignancies Database of the Department of Obstetrics and Gynecology.

Between January 2000 and December 2010, n = 658 patients were diagnosed with ovarian cancer at the Department of Obstetrics and Gynecology of the San Raffaele Scientific Institute. All patients with a primary diagnosis of invasive ovarian tumor of endometrioid histotype were

Results

Medical records and pathologic specimens were available for n = 65 patients diagnosed with endometrioid ovarian cancer (9.9%) in the considered time interval. Of these n = 65 patients, n = 21 (32%) had EAEOC and 44 (68%) had EOC. Clinical and morphological characteristics of the two groups are shown in Table 1. The mean age ± SD at diagnosis of the entire cohort was 60 ± 12 (range 37–87). Overall, age was significantly lower in patients without endometriosis (mean ± SD, 55 ± 10; range 39–73) versus

Discussion

The rate of malignant transformation of endometriosis into ovarian cancer has been estimated to be between 0.7% and 5% [28]. It is clinically well known that about one-third of all endometrioid and clear cell ovarian cancers arise from endometriosis. However, the distinguishing clinico-pathological features of endometriosis-associated ovarian tumors are still controversial. Some investigators have suggested that these tumors may be associated with young age, early-stage, low grade disease, and

Conclusions

We have herein confirmed that EAEOC presents at a younger age with an earlier stage and lower grade. Moreover, based on the fact that we detected a higher rate of concurrent endometrial cancer in EAEOC and considering the molecular data published so far, we dare to hypothesize a parallelism between endometrial and endometrioid ovarian carcinoma. This hypothesis represents the focus of our current and future research.

Conflict of interest statement

The authors declare no conflict of interest.

References (41)

  • P. Valenzuela et al.

    Endometrioid adenocarcinoma of the ovary and endometriosis

    Eur J Obstet Gynecol Reprod Biol

    (2007)
  • S. Pecorelli

    Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

    Int J Gynaecol Obstet

    (2009)
  • M. Signorelli et al.

    Synchronous early-stage endometrial and ovarian cancer

    Int J Gynaecol Obstet

    (2008)
  • D. Mayr et al.

    KRAS and BRAF mutations in ovarian tumors. A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

    Gynecol Oncol

    (2006)
  • R.J. Kurman et al.

    Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer — shifting the paradigm

    Hum Pathol

    (Jul 2011)
  • P.S. Munskgaard et al.

    The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations

    Gynecol Oncol

    (2012)
  • P. Viganò et al.

    Molecular mechanisms and biological plausability underlying the malignant transformation of endometriosis: a critical analysis

    Hum Reprod Update

    (2006)
  • A. Sayasneh et al.

    Endometriosis and ovarian cancer: a systematic review

    ISRN Obstet Gynecol

    (2011)
  • J.E. Olson et al.

    Postmenopausal cancer risk after self- reported endometriosis diagnosis in the Iowa women's health study

    Cancer

    (2002)
  • B. Eskanazi et al.

    Epidemiology of endometriosis

    Obstet Gynecol Clin North Am

    (1997)
  • Cited by (51)

    • MR Imaging of Epithelial Ovarian Neoplasms Part II: Malignant

      2023, Magnetic Resonance Imaging Clinics of North America
      Citation Excerpt :

      Peak incidence of clear cell carcinomas occur in perimenopausal women in their fifth and sixth decades.12 Similar to endometrioid carcinoma, clear cell carcinoma demonstrates an association with endometriosis.35,36 While the majority of patients are diagnosed in the early stages, given its relative insensitivity to platinum-based chemotherapeutic agents, clear cell carcinoma has a worse prognosis than serous or endometrioid carcinomas and is essentially considered high grade.3,12,35

    • Origins of Epithelial Ovarian Cancer

      2017, Translational Advances in Gynecologic Cancers
    View all citing articles on Scopus
    View full text